Every day, people are diagnosed with life-changing conditions, but often cannot afford the medicines they need.

Through leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the health care system, EQRx (NASDAQ: EQRX) is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices furthers it aim to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before.

EQRx has already made significant progress toward their mission starting with two potential therapies for the treatment of non-small cell lung cancer.  It now has a portfolio of over 10 programs.

In 2021, Jameel Health announced a partnership to become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.  In late-2020, the JIMCO Life Sciences fund became an enthusiastic investor in EQRx and further increased our commitment in 2021.

Visit: EQRx